search icon
      blog search icon

      Dare Bioscience, Inc. (DARE) Stock Rocketing Higher, Here’s the Reason - Stocks Telegraph

      By Hassan Masood

      Published on

      December 8, 2021

      6:25 AM UTC

      Dare Bioscience, Inc. (DARE) Stock Rocketing Higher, Here’s the Reason - Stocks Telegraph

      Dare Bioscience, Inc. (DARE), a clinical-stage biopharmaceutical company, has soared 37.61% in aftermarket trading session. Consequently, DARE is trading at $2.92 at the time of the writing. On Tuesday, DARE closed the day at $2.12 after surging 10.52% during regular trading hours. The increase in stock could be attributed to the approval of XACIATO by the FDA.

      Why DARE Rising?

      On Tuesday, DARE announced that the Food and Drug Administration (FDA) has approved XACIATO, clindamycin phosphate vaginal gel, 2%, for treating bacterial vaginosis in girls having age 12 years or older. Bacterial vaginosis is among the most common causes of vaginitis around the globe. It is estimated that vaginitis affects about 21 million women in the US alone. The FDA approval of XACIATO comes three years after the company licensed that technology.

      Q3 2021 Operational Results

      On 10th November, DARE released the operational results for the third quarter of fiscal 2021. The quarter ended on 30th September. The company bore total operating expenses of $12.6 million during the quarter against $7.5 million for the same period of 2020. The net loss suffered by the company during the three-month period stood at $12.66 million against $7.5 million for the same period of 2020. The net loss per basic and diluted share for the quarter stood at $0.18 against $0.24 for the same period of 2020.

      Executive Commentary

      While commenting on the results, Sabrina Martucci Johnson, President, and CEO of DARE said that the company has made continued efforts and significant progress on several of the key clinical and strategic corporative initiatives during the quarter. Based on those, the company is gearing up for eventful next few months and looks forward to providing updates as its progress continues in a forward direction.  

      Future Outlook for DARE

      During the last month, DARE stock has jumped up more than 32%. Based on that, analysts are predicting that dare stock should be on the radar of potential investors, who could reap numerous benefits from the stock in the near future.

      More From Stocks telegraph